Xalkori® (crizotinib) – New indication
July 14, 2022 - The FDA approved Pfizer’s Xalkori (crizotinib), for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is anaplastic lymphoma kinase (ALK)-positive.
Top